Information  X 
Enter a valid email address

Idorsia Ltd N Ord Shs (0RQE)

Date Time Source Announcement
05 Nov 2018 6:00 am
GNW
Idorsia maintains collaboration agreement with ReveraGen
24 Oct 2018 4:36 pm
GNW
Company statement
23 Oct 2018 6:02 am
GNW
Idorsia financial results for the first nine months of 2018
  6:00 am
GNW
Idorsia announces that Simon Jose is to join the company as Chief Commercial Officer
24 Jul 2018 6:00 am
GNW
Idorsia announces financial results for the first half 2018
19 Jul 2018 4:35 pm
GNW
Invitation to Idorsia's half year financial results 2018 webcast and conference call
11 Jul 2018 6:00 am
GNW
Idorsia successfully completes the offering of new shares and the offering of convertible bonds thereby securing long-term funding for the development of its advancing pipeline
20 Jun 2018 6:00 am
GNW
Idorsia initiates PRECISION - Phase 3 study with aprocitentan for resistant hypertension management
18 Jun 2018 6:00 am
GNW
Idorsia is initiating REACT - Phase 3 registration study with clazosentan
11 Jun 2018 6:00 am
GNW
Idorsia initiates a Phase 3 registration program with nemorexant (ACT-541468) for the treatment of insomnia
16 May 2018 6:00 am
GNW
Idorsia initiates MODIFY, a Phase 3 registration study to assess lucerastat as a potential new treatment option for patients with Fabry disease
24 Apr 2018 11:45 am
GNW
Idorsia holds its first Annual General Meeting of Shareholders - All Board proposals approved
19 Apr 2018 6:00 am
GNW
Idorsia announces financial results for the first quarter 2018
19 Mar 2018 6:00 am
GNW
Idorsia issues invitation to 2018 Annual General Meeting of Shareholders
06 Feb 2018 6:00 am
GNW
Idorsia announces financial results for 2017 - company off to a great start - 4 compounds to enter Phase 3 development
30 Jan 2018 4:40 pm
GNW
Invitation to Idorsia's full year results 2017 webcast and conference call
20 Dec 2017 6:00 am
GNW
Idorsia forms research collaboration with Roche in the field of cancer immunotherapy
04 Dec 2017 6:00 am
GNW
Idorsia announces collaboration with Janssen Biotech on aprocitentan (ACT-132577)
24 Oct 2017 6:00 am
GNW
Idorsia announces financial results as of 30 September 2017
16 Oct 2017 4:35 pm
GNW
Invitation to Idorsia's nine-month results 2017 webcast and conference call
03 Aug 2017 6:00 am
GNW
Idorsia announces half year results for 2017 - successful start of new biopharmaceutical company
28 Jul 2017 6:00 am
GNW
ACT-541468 (DORA) meets primary endpoint in Phase 2 program in adult and elderly patients with insomnia
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t